CYP2C9 and epilepsy: In vitro studies with human liver microsomes and clinical studies involving patients with epilepsy have shown that carriers of CYP2C9*2 and/or CYP2C9*3 alleles resulted in decreased valproate metabolism compared to individuals with CYP2C9*1/*1 wild-type genotypes17–19.